Here, our robust and scalable T cell killing assay evaluates the killing capacity of patient-derived tumor-infiltrating lymphocytes (TIL) in combination with immunomodulators to autologous human colorectal cancer tumor spheroids using Millicell ® Microwell 96-well plates.

In this chapter, we describe an optimized version of T cell suppression assay designed to test the capacity of immune co-stimulatory agents to enhance priming and activation of T cells in the presence of Tregs.

immune cell killing of adherent or non-adherent target tumor . cells. The flexible assay format is suitable for cytotoxic T cell killing and antibody-dependent cell-mediated cytotoxicity (ADCC) assays using a co-culture methodology that combines direct measurements of tumor cell death with no-wash, mix-and-read protocols.

Our purpose was to validate the killing assay for the evaluation of autologous anti-CD19 chimeric antigen receptor (CAR) T potency. We used CD4 + and CD8 + lymphocytes or anti-CD19 CAR-T cells as effector cells and REH (CD19 +) or MOLM-13 (CD19 −) cell lines as target cells.

2010年7月29日 · Here we report a new method that we recently developed for quantifying antigen-specific cytolytic activity of CTLs. This method fully exploits the high sensitivity and the relative simplicity of luciferase quantitative assay, while …

2020年12月1日 · We demonstrated that splenocytes and tumor-infiltrating T cells derived from mice treated with combination therapy were able to kill approximately 50% of target cells after 48 h of co-culture. This effect was tumor cell-specific and dependent on CD8 + T cells evidenced by in vitro CD8 + T cell depletion.

Incucyte Immune Cell Killing Assays allows for direct, multiplexed measurements of immune cell-mediated killing of tumor cells via the combination of real-time, automated analysis along with non-perturbing, live-cell reagents – all within your tissue culture incubator.

T cell killing assays measure a drug’s potency to help T cells kill tumor cells. T cell killing assays are a valuable tool for immuno-oncology discovery projects for in vitro assessment of new drug candidates to: Understand the immune-modulating action of new immunotherapeutics; Optimize the potency of new drugs

The flexible assay format is suitable for cytotoxic T cell killing and antibody-dependent, cell-mediated cytotoxicity (ADCC) assays using a co-culture methodology that combines direct measurements of tumor cell death with no-wash, mix-and-read protocols.

Enhancing DC-mediated tumor antigen presentation triggers priming of specific cytotoxic lymphocytes thereby inducing an adaptive effector T cell-mediated killing response.

In vitro tumor killing assays offer the ability to recapitulate aspects of cellular and humoral interactions found in tumors. Immune mediated tumor cell killing is kinetically assessed by combining fluorescently labelled target cells with PBMC in the presence of an apoptosis reporter.

CD19-BiTE enhances T cell-mediated B cell killing measured by an RTCA biosensor assay. Daudi target cells were seeded at 50,000 cells/well in an Agilent 96‑well E‑Plate coated with αCD40 antibody.

High specificity of CAR T cell-mediated killing ensures safety and effectiveness of a CAR T cell therapy. HER2-overexpressing cancer cells were treated with CAR T cells with or without the tumor antigen-recognizing domain.

We demonstrated that splenocytes and tumor-infiltrating T cells derived from mice treated with combination therapy were able to kill approximately 50% of target cells after 48 h of co-culture. This effect was tumor cell-specific and dependent on CD8 + …

2020年9月1日 · Agilent Technologies describes a CAR T-cell killing assay that combines the sensitivity and objectivity of real-time impedance monitoring with the highly specific readouts of live-cell imaging.

Here we describe two methods to evaluate CAR T cell-mediated cytotoxicity in response to repeated antigen stimulation in vitro, otherwise known as a repeated challenge assay.

In this study, we demonstrate a noninvasive immunotherapy potency assay using the Maestro Z, a platform that can continuously monitor cell-mediated killing and capture the cytolysis kinetics.

Here, we compare various in vitro cytotoxicity assays (including chromium release, bioluminescence, impedance, and flow cytometry) with respect to experimental setup, appropriate uses, advantages, disadvantages, and measures to overcome limitations.

The iQue ® Human T Cell Killing application utilizes the iQue ® Human T Cell Killing Kit for simultaneous, high-throughput analysis of T cell phenotypic and activation marker expression, target cell killing and quantification of secreted effector proteins and cytokines.

4 天之前 · Killing assays of CAR-T cells expressing CAR-TM mutants were performed at a 5-to-1 effector-to-target ratio for 18 to 24 hours. Luciferase readouts were obtained lysing the cells using the ONE-Glo Luciferase Assay Kit (Promega, no. E6110), and results were read using a luminescence reader to assess tumor cell viability.

We describe here a new cell-based assay to measure the capacity of antigen-specific CD8+ T cells to kill CD4+ T cells loaded with their cognate peptide. Target CD4+ T cells are divided into two populations, labeled with two different concentrations of CFSE.

2 天之前 · The immune-related adverse events associated with chimeric antigen receptor (CAR)-T cell therapy result in substantial morbidity as well as considerable cost to the health-care system, and can ...